Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays

Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays

Abstract Background Mycobacterium tuberculosis (MT) infections represent a global health problem and latent tuberculosis infection (LTBI) affects an estimated 25% of the world population. 10.6 million people fell ill with tuberculosis (TB) worldwide in 2021 and a total of 1.6 million TB-associated d...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sandra Schwarzlose-Schwarck, Mark Reinwald, Torsten Bauer, Florian Hentschel, Til Kiderlen, Dorinja Zapf, Victor Herbst, Stefan Lüth, David Krieger, Werner Dammermann
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Series:	BMC Infectious Diseases
Subjects:	Tuberculosis IGRA Complement factors TLR agonists Interferon gamma release assay
Online Access:	https://doi.org/10.1186/s12879-025-10577-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes
by: S.J.W. Kang, et al.
Published: (2024-10-01)

Prevalence, incidence and determinants of QuantiFERONTM positivity in South African schoolchildren
by: J. Stewart, et al.
Published: (2024-05-01)

Comparative Performance of Ante-Mortem Diagnostic Assays for the Identification of <i>Mycobacterium bovis</i>-Infected Domestic Dogs (<i>Canis lupus familiaris</i>)
by: Conor O’Halloran, et al.
Published: (2025-01-01)

Editorial: Immunology of food-borne parasites: recent progress and future advances
by: Saeed El-Ashram, et al.
Published: (2025-01-01)

Therapeutic effects of platelet-derived extracellular vesicles on viral myocarditis correlate with biomolecular content
by: Danielle J. Beetler, et al.
Published: (2025-01-01)

Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
by: Jarosz-Biej Magdalena, et al.
Published: (2025-02-01)

The effect of interferon alpha administration on cytokine levels in sheep
by: Devran Coşkun, et al.
Published: (2020-12-01)

Effects of different vaccination regimes on the immunodiagnosis of tuberculosis in goats and evaluation of defined antigens
by: Patricia Cuenca-Lara, et al.
Published: (2025-01-01)

The concerted actions of microRNA-29a and interferon-β modulate complete Freund's adjuvant-induced inflammatory pain by regulating the expression of type 1 interferon receptor, interferon-stimulated gene 15, and p-extracellular signal-regulated kinase
by: Chien-Cheng Liu, et al.
Published: (2025-03-01)

HIV and diabetes impair M. tuberculosis-specific interferon-gamma responses on QuantiFERON-TB Gold Plus testing
by: J.S. Zifodya, et al.
Published: (2024-05-01)

Preliminary Diagnosis and Characterization of a Spontaneous Immature Testicular Teratoma in an Interferon Receptor-Deficient Mouse Model
by: ZHAO He, et al.
Published: (2024-12-01)

Diagnostic value of interferon-γ release assay in patients with COPD complicated with pulmonary tuberculosis
by: Yanxiao Rong, et al.
Published: (2025-01-01)

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome
by: Kira A Cozzolino, et al.
Published: (2025-02-01)

Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
by: Leslie Pérez Ruiz, et al.
Published: (2007-12-01)

Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect
by: Xiyuan Wang, et al.
Published: (2025-01-01)

Divergent Effects of <i>Circoviridae</i> Capsid Proteins on Type I Interferon Signaling
by: Anon H. Kosaka, et al.
Published: (2025-01-01)

Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01)

Comparative performance of tuberculin and defined-antigen cocktails for detecting bovine tuberculosis in BCG-vaccinated cattle in natural settings
by: Abebe Fromsa, et al.
Published: (2025-02-01)

On certain quasi-complemented and complemented Banach algebras
by: Pak-Ken Wong
Published: (1978-01-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022-10-01)

Case report: Exploring efficacy of tofacitinib in modulating interferon response in five case of anti-MDA5+ dermatomyositis with interstitial lung disease
by: Jie Zhao, et al.
Published: (2025-02-01)

Interferon-Stimulated Genes and Immune Metabolites as Broad-Spectrum Biomarkers for Viral Infections
by: Chien-Hsin Huang, et al.
Published: (2025-01-01)

ZBP1 senses Brucella abortus DNA triggering type I interferon signaling pathway and unfolded protein response activation
by: Marco Túlio R. Gomes, et al.
Published: (2025-01-01)

Acidosis activates complement system in vitro
by: Michael Emeis, et al.
Published: (1998-01-01)

Heightened expression of type I interferon signaling genes in CD4+ T cells from acutely HIV-1–infected women is associated with lower viral loads
by: Elina El-Badry, et al.
Published: (2025-01-01)

Species- and strain-specific microbial modulation of interferon, innate immunity, and epithelial barrier in 2D air–liquid interface respiratory epithelial cultures
by: Mian Horvath, et al.
Published: (2025-01-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Interaction of toll-like receptors and ACE-2 with different variants of SARS-CoV-2: A computational analysis
by: Azadeh Zahmatkesh, et al.
Published: (2024-07-01)

Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
by: Michael L. McCaleb, et al.
Published: (2025-03-01)

Complement activation in wasp venom-induced acute kidney injury
by: Rui Cheng, et al.
Published: (2024-12-01)

Terminal complement complex deposition on chondrocytes promotes premature senescence in age- and trauma-related osteoarthritis
by: Leonie Ruths, et al.
Published: (2025-01-01)

An artificial transcription factor that activates potent interferon-γ expression in human Jurkat T Cells
by: Ashley King, et al.
Published: (2025-01-01)

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)

Regulation of interferon alpha production by the MAGUK-family protein CASK under H5N1 infection
by: Jing-Ying Huang, et al.
Published: (2025-01-01)

Mapping integral cell-type-specific interferon-induced gene regulatory networks (GRNs) involved in systemic lupus erythematosus using systems and computational analysis
by: Blessy Kiruba, et al.
Published: (2025-01-01)

Developing Costimulatory Molecules for Immunotherapy of Diseases /
by: Mir, Manzoor Ahmad
Published: (2015)

Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long‐Term Cardiovascular Mortality
by: Mieke C. Louwe, et al.
Published: (2025-02-01)

On the margins of perception - TO-clauses: a standard construction of perception verbs?
by: Christelle LACASSAIN-LAGOIN
Published: (2018-06-01)